Vaccine Economics and Policy in Morocco: Financing, Efficiency, Access, and the Transition Toward Health Sovereignty

Introduction: Vaccination is a public health intervention, an economic investment, and a health-security instrument. In Morocco, the national immunization program (PNI) has progressively expanded to include newer vaccines, while the COVID-19 pandemic reinforced concerns over supply security, logistical resilience, and local production.
Objective: To analyze the evolution of vaccine economics and policy in Morocco, focusing on financing, the introduction of new vaccines, economic evaluation data, access, supply chains, and the transition toward greater industrial autonomy.
Methods: A scoping review mapped available evidence on vaccine economics and policy in Morocco, combining Scopus, PubMed/MEDLINE, Web of Science Core Collection, and ScienceDirect, supplemented by relevant institutional sources. Selection, extraction, and synthesis followed PRISMA-ScR principles, and studies were classified by relevance to Morocco and by the economic, programmatic, logistical, financial, and industrial dimensions examined.
Results: The Moroccan literature shows an economic evidence base that is still limited but now better structured, with the most robust data concerning rotavirus and HPV. PubMed confirmed the Moroccan rotavirus economic evaluation by Mohy et al. [2], while Web of Science and ScienceDirect broadened the analysis to vaccine financing, procurement, pricing, local production, and African industrial capacity. The systematic review by Bishop et al. [1], covering 26 economic evaluations (12 HPV, 9 rotavirus, 5 pneumococcal), concludes that PCV and rotavirus vaccination are generally economically favorable and that HPV vaccination is generally cost-effective in Morocco. The evidence converges on the importance of assessing total program cost, budget impact, financing sustainability, and the economic viability of local production, beyond acquisition price alone.
Conclusion: Morocco is moving from a model centered on vaccination coverage toward an integrated policy combining prevention, economic efficiency, budget sustainability, supply security, local production, and African cooperation. Developing cost-effectiveness, cost-utility, and budget-impact analyses based on national data appears essential to guide future vaccination decisions.

vaccination; health economics; vaccine policy; cost-effectiveness; Morocco

1. Bishop, C., Politopoulou, K., Bermudez, M., Rodriguez-Cairoli, F., Abeshu, M., Kadandale, S., Oyatoye, I., & Farrukh, S. (2026). Economic evaluations of new vaccine introduction in middle-income countries in the Middle East and North Africa region: A systematic review. Vaccines, 14(7), 591. https://doi.org/10.3390/vaccines14070591 [Google Scholar] [Crossref]

2. Mohy, A., Lagoubi, Y., Gomez, J. A., Amadou, B., & Bouskraoui, M. (2024). Health economic evaluation of 2-dose and 3-dose rotavirus vaccines in children below 5 years of age in Morocco. Human Vaccines & Immunotherapeutics, 20(1), 2353480. https://doi.org/10.1080/21645515.2024.2353480 [Google Scholar] [Crossref]

3. Bishop, C., Parashar, D., Kizza, D., et al. (2025). New vaccine introduction in middle-income countries across the Middle East and North Africa—Progress and challenges. Vaccines, 13(8), 860. https://doi.org/10.3390/vaccines13080860 [Google Scholar] [Crossref]

4. Onishchenko, K., Hill, S., Wasserman, M., Jones, C., Moffatt, M., Ruff, L., & Pugh, S. J. (2019). Trends in vaccine investment in middle income countries. Human Vaccines & Immunotherapeutics, 15(10), 2378–2385. https://doi.org/10.1080/21645515.2019.1589287 [Google Scholar] [Crossref]

5. Benhafid, M., Youbi, M., Klena, J. D., Gentsch, J. R., Teleb, N., Widdowson, M. A., & Elaouad, R. (2009). Epidemiology of rotavirus gastroenteritis among children <5 years of age in Morocco during 1 year of sentinel hospital surveillance, June 2006–May 2007. Journal of Infectious Diseases, 200(Suppl 1), S70–S75. https://doi.org/10.1086/605048 [Google Scholar] [Crossref]

6. Benhafid, M., Elomari, N., Azzouzi Idrissi, M., Rguig, A., Gentsch, J. R., Parashar, U., & Elaouad, R. (2015). Effect of monovalent rotavirus vaccine on rotavirus disease burden and circulating rotavirus strains among children in Morocco. Journal of Medical Virology, 87(6), 944–953. https://doi.org/10.1002/jmv.24122 [Google Scholar] [Crossref]

7. Barlow, R. (1976). Applications of a health planning model in Morocco. International Journal of Health Services, 6(1), 103–122. [Google Scholar] [Crossref]

8. Messoudi, W., Elmahi, T., Nejjari, C., Tachfouti, N., Zidouh, A., Saadani, G., Moriña, D., & Diaz, M. (2019). Cervical cancer prevention in Morocco: A model-based cost-effectiveness analysis. Journal of Medical Economics, 22(11), 1153–1159. https://doi.org/10.1080/13696998.2019.1624556 [Google Scholar] [Crossref]

9. Nagi, M. A., Luangsinsiri, C., & Thavorncharoensap, M. (2021). A systematic review of economic evaluations of vaccines in Middle East and North Africa countries: Is existing evidence good enough to support policy decision-making? Expert Review of Pharmacoeconomics & Outcomes Research, 21(6), 1159–1178. https://doi.org/10.1080/14737167.2021.1954508 [Google Scholar] [Crossref]

10. Aslaou, F., Ibrahimi, H., Rahali, K., Achachi, H., Abbassi, I., Soulaymani, A., et al. (2024). Study of the epidemiological profile of cervical cancer in two screening cohorts (HPV 16.18) and analysis of their cost per activity in the Rabat region in Morocco (vaccine vs. therapy). International Journal of Chemical and Biochemical Sciences, 25(15), 92–100. [Google Scholar] [Crossref]

11. Arechkik, A., Lahlou, L., Obtel, M., Kharbach, A., & Razine, R. (2022). Cervical cancer in Morocco: A systematic review [Article in French]. Revue d’Épidémiologie et de Santé Publique, 70(5), 230–242. [Google Scholar] [Crossref]

12. Haeuser, E., Byrne, S., Nguyen, J., et al. (2025). Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: A systematic analysis for the Global Burden of Disease Study 2023. The Lancet, 406(10500). [Google Scholar] [Crossref]

13. Hajizadeh, M. (2018). Socioeconomic inequalities in child vaccination in low/middle-income countries: What accounts for the differences? Journal of Epidemiology and Community Health, 72(8). [Google Scholar] [Crossref]

14. Tsega, C. (2025). Ensuring vaccine access through local production: The need for a harmonized and sustainable approach. Journal of Law and the Biosciences, 12(2), lsaf020. https://doi.org/10.1093/jlb/lsaf020 [Google Scholar] [Crossref]

15. Ministry of Industry and Trade, Kingdom of Morocco. (n.d.). Launch of construction work in Benslimane on a manufacturing plant for anti-COVID-19 and other vaccines [Institutional document]. [Google Scholar] [Crossref]

16. Marbio. (2026). Sanofi and Marbio conclude a strategic and industrial partnership in Morocco [Institutional press release]. [Google Scholar] [Crossref]

17. Ministry of Economy and Finance, Kingdom of Morocco. (2026, May 4). Signing of the Grant Agreement between the Government of the Kingdom of Morocco and the Gavi Vaccine Alliance. [Google Scholar] [Crossref]

18. Mzili, T., Mzili, I., Riffi, M. E., et al. (2024). Enhancing COVID-19 vaccination and medication distribution routing strategies in rural regions of Morocco: A comparative metaheuristics analysis. Informatics in Medicine Unlocked, 46, 101467. [Google Scholar] [Crossref]

19. Benchekroun, H. T., Benmamoun, Z., & Hachimi, H. (2022). Implementation and sustainability assessment of a public procurement strategy. Sustainability, 14(23), 15565. [Google Scholar] [Crossref]

20. Ussai, S., Chillotti, C., Stochino, E., et al. (2022). Building the momentum for a stronger pharmaceutical system in Africa. International Journal of Environmental Research and Public Health, 19(6), 3313. [Google Scholar] [Crossref]

21. Berrada, M., Holl, R., Ndao, T., et al. (2021). Healthcare resource utilization and costs associated with anogenital warts in Morocco. Infectious Agents and Cancer, 16(1), 64. [Google Scholar] [Crossref]

22. Bennani Mechita, N., Obtel, M., Elmarnissi, A., et al. (2020). Decline in childhood respiratory-related mortality after the introduction of the pneumococcal conjugate vaccine in Morocco. Journal of Infection and Public Health, 13(3). [Google Scholar] [Crossref]

23. Chikhaoui, A., Nzoyikorera, N., Diawara, I., Jouhadi, Z., & Zerouali, K. (2022). Burden of invasive pneumococcal disease in children in Casablanca, Morocco four years after the introduction of pneumococcal vaccination. Pan African Medical Journal, 41, 2. [Google Scholar] [Crossref]

24. Regragui, Z., Bimouhen, A., El Falaki, F., et al. (2022). Influenza-associated severe acute respiratory infections among children under five years old in Morocco, September 2017 to March 2019. Infezioni in Medicina, 30(3). [Google Scholar] [Crossref]

25. Ezzine, H., Regragui, Z., Cherkaoui, I., et al. (2023). Factors associated with hospitalization for seasonal influenza in Morocco. Eastern Mediterranean Health Journal, 29(6). [Google Scholar] [Crossref]

26. Levin, A., Ram, S., & Kaddar, M. (2002). The impact of the Global Polio Eradication Initiative on the financing of routine immunization: Case studies in Bangladesh, Côte d’Ivoire and Morocco. Bulletin of the World Health Organization, 80(10), 822–828. [Google Scholar] [Crossref]

27. Jumaan, A. O., Ghanem, S., Taher, J., et al. (2013). Prospects and challenges in the introduction of human papillomavirus vaccines in the extended Middle East and North Africa region. Vaccine, 31(Suppl 6). [Google Scholar] [Crossref]

28. Bouazzaoui, N. L. (2006). Evolution of the vaccination schedule in Morocco [Article in French]. Bulletin de l’Académie Nationale de Médecine, 190(4–5), 1017–1032. [Google Scholar] [Crossref]

29. Jroundi, I., Benazzouz, M., Yahyane, A. H., Alaoui, M. T., & El Omeiri, N. (2021). Moroccan National Immunization Technical Advisory Group: A valuable asset for the national immunization program and the immunization agenda in the EMRO region. Human Vaccines & Immunotherapeutics, 17(8), 2788–2792. [Google Scholar] [Crossref]

30. Mouallif, M., Bowyer, H. L., Festali, S., et al. (2014). Cervical cancer and HPV: Awareness and vaccine acceptability among parents in Morocco. Vaccine, 32(3), 409–416. [Google Scholar] [Crossref]

31. Baddouh, N., Rada, N., Elalouani, F. E., Draiss, G., & Bouskraoui, M. (2018). Acceptability of human papilloma virus vaccine: Parent survey. Pan African Medical Journal, 31, 71. [Google Scholar] [Crossref]

32. Abouqal, R., Beji, M., Chakroun, M., et al. (2022). Trends in adult and elderly vaccination: Focus on vaccination practices in Tunisia and Morocco. Frontiers in Public Health, 10, 903376. [Google Scholar] [Crossref]

33. Mohammed, A., Idris-Dantata, H., Okwor, T., et al. (2023). Supporting the manufacturing of medical supplies in Africa: Collaboration between Africa CDC, partners, and member states. Global Health: Science and Practice, 11(5), e2300121. [Google Scholar] [Crossref]

34. de Beer, J. C., Goto, D., Bencina, G., et al. (2022). Vaccine financing in the Middle East and Africa: An overview from 2010 to 2019. Vaccine. [Google Scholar] [Crossref]

35. Kaddar, M., Saxenian, H., Sadr-Azodi, N., et al. (2019). Vaccine procurement in the Middle East and North Africa region: Challenges and ways of improving program efficiency and fiscal space. Vaccine. [Google Scholar] [Crossref]

36. Sim, S. Y., Watts, E., Constenla, D., et al. (2021). Costs of immunization programs for 10 vaccines in 94 low- and middle-income countries from 2011 to 2030. Value in Health, 24(1). [Google Scholar] [Crossref]

37. Osei, C. K., Nketiah-Amponsah, E., & Otchere, F. (2024). Vaccine pricing and production capacity in Africa: Can Africa move beyond pooled procurement in the face of a future pandemic? Global Health Journal. [Google Scholar] [Crossref]

38. Doua, J., Ndembi, N., Zumla, A., et al. (2025). Advancing local manufacturing capacities for vaccines within Africa—Opportunities, priorities and challenges. Vaccine. [Google Scholar] [Crossref]

39. Tanriover, M. D., Vallee-Tourangeau, G., et al. (2025). The vaccination acceptance, confidence, and conviction on influenza in the Middle East, Eurasia, and Africa among healthcare providers (VACCIMENA-HCP) project 2023: Determinants of vaccination behavior. IJID Regions, 14. [Google Scholar] [Crossref]

40. Abidi, S., Labani, S., Singh, A., Asthana, S., & Ajmera, P. (2020). Economic evaluation of human papillomavirus vaccination in the Global South: A systematic review. International Journal of Public Health, 65(7). [Google Scholar] [Crossref]

• Impact of Foreign Direct Investment in India
• Issues Involved in Digitalisation Special Reference to Indian Tourism Growth
• Relationship Marketing and Customer Loyalty in the Fast-Moving Consumer Goods (FMCG) Industry in Nairobi County
• Financial Literacy or Financial Inclusion? Which is Which, What is What—To Achieve Uganda’s 10-Fold Economic Growth By 2040
• Harnessing Natural Gas for Economic Transformation: Overcoming the Regulatory and Infrastructural Bottlenecks in Nigeria